# A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

> **NCT00355355** · PHASE3 · COMPLETED · sponsor: **Light Sciences Oncology** · enrollment: 208 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Liver Neoplasms

## Interventions

- **DRUG:** Talaporfin sodium
- **DEVICE:** Interstitial Light Emitting Diodes
- **PROCEDURE:** Percutaneous placement of device in the liver
- **PROCEDURE:** Standard Care

## Key facts

- **NCT ID:** NCT00355355
- **Lead sponsor:** Light Sciences Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2015-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355355, "A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00355355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*